bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance Read more about bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance
bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call Read more about bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call
bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital Read more about bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy Read more about bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
bluebird bio Fourth Quarter and 2023 Annual Results Conference Call Read more about bluebird bio Fourth Quarter and 2023 Annual Results Conference Call
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook Read more about bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook
42nd Annual J.P. Morgan Healthcare Conference Read more about 42nd Annual J.P. Morgan Healthcare Conference
bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference Read more about bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock Read more about bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock